Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Sunshine Biopharma, Inc. focuses on developing innovative cancer therapeutics, particularly targeting drug-resistant cancers. Its competitive position is bolstered by proprietary drug formulations, including Adva-27a, which has shown promise in preclinical studies. The company operates primarily in North America, with potential for global expansion as it advances through clinical trials.
Sunshine Biopharma generates revenue through the development and commercialization of cancer treatment drugs. The company leverages its proprietary technology to create unique drug formulations, which provides pricing power in a competitive market. Its focus on drug-resistant cancers positions it uniquely against larger pharmaceutical companies.
Progress in clinical trials for Adva-27a and other drug candidates
Partnerships or licensing agreements with larger pharmaceutical companies
Regulatory approvals from the FDA or other health authorities
Market sentiment regarding the oncology drug market
Regulatory changes impacting drug approval processes
Technological disruption in cancer treatment methodologies
Emergence of new therapies from larger pharmaceutical companies
Potential for generic competition once patents expire
Limited cash flow and negative free cash flow could impact operational sustainability
Dependence on external funding for ongoing clinical trials
moderate - The demand for pharmaceuticals can be somewhat insulated from economic cycles, but funding for R&D may be affected during downturns.
Interest rates affect the company's ability to finance R&D activities. Higher rates may increase the cost of capital, impacting future growth potential.
minimal - The company has low debt levels, which reduces its exposure to credit market fluctuations.
growth - Investors looking for high-risk, high-reward opportunities in the biotech space may find this company appealing.
high - The stock has exhibited significant volatility, particularly given its recent performance and the speculative nature of biotech investments.
